DDrare: Database of Drug Development for Rare Diseases

Searched query = "Stevens-Johnson syndrome", "SJS", "Mucocutaneous ocular syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 0.05%cyclosporin eye drop; 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine; Cultivated oral mucosal epithelial sheet transplantation; Cyclosporin; Cyclosporine; Cyclosporine 5 mg/kg bid days 0-14; Etanercept; Etanercept 50 mg sc day 0 and day 3; Harmonized supportive care; Infliximab; Intravenous immunoglobulin; Lamotrigine; Lamotrigine - generic product; Methylprednisolone; Palifermin; Prednisolone; Riboflavin; Site specific standard of care comparison; Topical infliximab

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01696500 (ClinicalTrials.gov)	October 2012	20/9/2012	Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.	NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.	Stevens-Johnson Syndrome;Toxic Epidermal Necrolysis	Drug: Intravenous immunoglobulin	Nihon Pharmaceutical Co., Ltd	NULL	Completed	20 Years	N/A	Both	10	Phase 3	Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01696500
(ClinicalTrials.gov)

October 2012

20/9/2012

Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.

NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.

Stevens-Johnson Syndrome;Toxic Epidermal Necrolysis

Drug: Intravenous immunoglobulin

Nihon Pharmaceutical Co., Ltd

NULL

Completed

20 Years

N/A

Both

Phase 3

Japan